Sunday November 8 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Neuroendocrine Tumors

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Neuroendocrine Tumors:

Pubmed Logo
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
ABSTRACT: The mammalian target of rapamycin (mTOR) is an intracellular...
29th October, 2009
J Hematol Oncol. 2009 Oct 27;2(1):45.
DOI Direct Link
Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas.
AIM: To assess the patient-reported outcomes (PROs) of pancreatic...
28th October, 2009
Department of Digestive Diseases and Internal Medicine, World J Gastroenterol. 2009 Oct 28;15(40):5067-73.
Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes.
AIMS AND BACKGROUND: Carcinoids are infrequent neoplasms arising from...
28th October, 2009
Unit of Medical Oncology2, Centro di Riferimento per lo Studio e la Cura Tumori. 2009 Jul-Aug;95(4):501-7.
Twenty-Five-Year Follow-up for Liver Resection: The Personal Series of Dr. Joseph G. Fortner.
BACKGROUND:: Liver resection is performed for many types of malignancies....
27th October, 2009
From the Memorial Sloan-Kettering Cancer Center, New York, NY. Ann Surg. 2009 Oct 21.
DOI Direct Link
Biochemical testing for neuroendocrine tumors.
In this review, we focus on the use of biochemical markers for the...
27th October, 2009
Eastern Virginia Medical School, Strelitz Diabetes Research Center, Pancreas. 2009 Nov;38(8):876-89.
DOI Direct Link

View more research publications.

Press Releases About Neuroendocrine Tumors:

BioPortfolio Logo
AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2nd November, 2009 AETERNA ZENTARIS INC.
Preliminary evaluation after completion of treatment phase shows that primary efficacy endpoint has been met for patients with advanced-stage platinum-resistant, taxane-pretreated ovarian
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 26th October, 2009 Reportlinker
-- A focus on "engineered" antibodies Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
Ascenta Therapeutics Announces Presentation of Results From a Dose-Ranging Study of AT-101 With Standard Therapy in Patients With Glioblastoma Multiforme 26th October, 2009 Ascenta Therapeutics, Inc.
MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral,
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer 23rd October, 2009 Onyx Pharmaceuticals, Inc.
WAYNE, N.J. and EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun
NexGenix Pharmaceuticals Awarded Phase I Grant from the National Institute of Neurological Disorders and Stroke (NINDS) Small Business Innovation Research Program (SBIR) for the Development of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma 22nd October, 2009 NexGenix Pharmaceuticals Holdings, Inc.
NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. a privately-held biotechnology company with a portfolio of novel targeted therapies for oncology and neurodegenerative

BioNews Results for Neuroendocrine Tumors:

RSS Logo
BioPortfolio Logo
Biochemical Testing for Neuroendocrine Tumors
MDLinx:  Oct 23 2009 11:13AM Matching: neuroendocrine tumors
Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols
MDLinx:  Oct 8 2009 12:29PM Matching: neuroendocrine tumors
Molecular Insight Pharmaceuticals Presents Azedra Efficacy Data in Neuroendocrine Tumors
Pharma Live:  Oct 6 2009 2:39AM Matching: neuroendocrine tumors
Molecular Insight Pharmaceuticals Presents Azedra(TM) 12-Month Efficacy Data From Phase I Clinical Trial in Neuroendocrine Tumors
Individual.com:  Oct 5 2009 12:49PM Matching: neuroendocrine tumors
Molecular Insight Pharmaceuticals Presents AzedraTM 12-Month Efficacy Data From Phase I Clinical Trial In Neur
Medical News Today:  Oct 6 2009 10:11AM Matching: neuroendocrine tumors
Promote your company here: BioNewsCast - Press Release Distribution

View more news.

Neuroendocrine Tumors Clinical Trials:

Clinical Trials Logo
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors Patents:

USPTO Logo
US Patent No.Title
7449549 PRO9822 polypeptides
7485308 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor
7488586 PRO4409 polypeptides
7488588 Compounds related to or derived from GFR .alpha.4 and their use
7488796 PRO1269 polypeptides

View more patents.

Companies working in the area of Neuroendocrine Tumors from Bioportfolio's Biocorporate database :

BioPortfolio Logo
Company Name

Tercica

Tercica, Inc., based in Brisbane, Calif., is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the scientific and medical community to...
www.tercica.com/        View full profile
Thumbshot

Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat...
www.molecularinsight.com/        View full profile
Thumbshot

BioPortfolio Ltd. offers e-mail and postal lists for Neuroendocrine Tumors scientists - we have details of around 291 individuals working on Neuroendocrine Tumors .


This page has been viewed 450 times
Recent Search Terms used to find this page: neuroendocrine tumour, e-medicine | neuroendocrine tumors | neuroendocrine tumors news | neuroendocrine tumors of pancreas | neuroendrocrine 2009 | Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning | video of pancreas neuroendocrine tumor | any new news on neuro endocrine tumors | neuroendocrine tumour patholgy | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Neuroendocrine Tumors across BioPortfolio, or for Neuroendocrine Tumors Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.